S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
AIDX$0.2371+0.89%
20/20 Biolabs, Inc.
Sector: Services-Testing LaboratoriesIndustry: Medical - Care FacilitiesCountry: USExchange: Nasdaq
Mkt Cap:$3.03M
Float & O/S:
Inst Own:
DilutionScan read 20 of 20/20 Biolabs, Inc.'s SEC filings and found 8 warrant series, 11 convertibles, 1 equity line, 2 S-1 registrations and 6 completed offerings on file for AIDX. The latest dilution event on file is an offering on Jun 16, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
AIDX
Unprofitable micro-cap with comfortable cash runway
Snapshot
AIDX is an unprofitable micro-cap clinical laboratory testing company with growing revenue. FY 2025 revenue was $2.0M, up 16.7% year-over-year, but the company posted a net loss of $3.7M.
What's Happening Right Now
- : The company highlighted themes from its investor webinar, focusing on positioning OneTest for Medicare reimbursement, enabling serial biomarker tracking, and noting strong Q2 revenue growth.
- : The State of Vermont selected the OneTest blood test to screen up to 4,500 firefighters in a twelve-month contract expected to generate approximately $500,000 in testing revenues.
- : 20/20 BioLabs reported Q1 2026 revenue of $353K, down from the prior year due to order timing, but strengthened its balance sheet with a $5M private placement bringing cash to $4.2M.
- : 20/20 BioLabs exclusively licensed a patented PSA Velocity algorithm from the University of South Carolina to help identify dangerous prostate tumors earlier.
Raise routes on file: effective S-1 + active equity line · latest dilution event 140 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jun 16, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible Promissory Notes – Private Placement (January 2025)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series E Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series A Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Equity line
Issued 2025
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your AIDX trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
